Search

Your search keyword '"Rampal, Raajit"' showing total 1,067 results

Search Constraints

Start Over You searched for: Author "Rampal, Raajit" Remove constraint Author: "Rampal, Raajit"
1,067 results on '"Rampal, Raajit"'

Search Results

1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era

2. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

3. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

4. Biological drivers of clinical phenotype in myelofibrosis

6. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

7. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies

8. Single-cell mutation analysis of clonal evolution in myeloid malignancies

9. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

10. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

13. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

14. Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

16. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

18. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

19. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression

21. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

24. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results

25. Interferons in the treatment of myeloproliferative neoplasms

26. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

28. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease

30. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

31. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin

32. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

34. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

35. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

36. Survival following allogeneic transplant in patients with myelofibrosis

38. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

39. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

40. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

41. MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis

42. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

45. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms*

49. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis

Catalog

Books, media, physical & digital resources